Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2443-2449

  Rigatto, Maria Helena ^a,b   Oliveira, Maura S ^c   Perdigão Neto, Lauro V ^c   Levin, Anna S ^c   Carrilho, Claudia M ^d   Tanita, Marcos Toshiyuki ^d   Tuon, Felipe F ^e   Cardoso, Douglas E ^e   Lopes, F Natane T ^f   Falci, Diego R ^b,g   Zavascki, Alexandre P ^b,f  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^g HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; POLYMYXIN B; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ABDOMINAL INFECTION; ADULT; ARTICLE; BLOODSTREAM INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; END STAGE RENAL DISEASE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ACUTE KIDNEY INJURY; AGE; AGED; ANALOGS AND DERIVATIVES; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; INTRAABDOMINAL INFECTIONS; KIDNEY FAILURE, CHRONIC; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOGENICITY; PATHOLOGY; RESPIRATORY TRACT INFECTIONS; RISK FACTOR; SURVIVAL ANALYSIS; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BODY WEIGHT; COLISTIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; INTRAABDOMINAL INFECTIONS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMYXIN B; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84963684468     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02634-15     Document Type: Article

References (26)

1. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: Peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093/cid/ciu213.
2. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231-2237. http://dx.doi.org/10.1093/jac/dkq285.
3. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. 2011. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66:175-179. http://dx.doi.org/10.1093/jac/dkq390.
4. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L. 2010. Effectiveness and safety of colistin: Prospective comparative cohort study. J Antimicrob Chemother 65:1019-1027. http://dx.doi.org/10.1093/jac/dkq069.
5. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300-1303. http://dx.doi.org/10.1093/cid/cit453.
6. Deryke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54:4503-4505. http://dx.doi.org/10.1128/AAC.01707-09.
7. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary caremedical center. Clin Infect Dis 48:1724-1728. http://dx.doi.org/10.1086/599225.
8. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. 2012. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65:80-87. http://dx.doi.org/10.1016/j.jinf.2012.01.015.
9. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740-2746. http://dx.doi.org/10.1128/AAC.02476-13.
10. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43:349-352. http://dx.doi.org/10.1016/j.ijantimicag.2013.12.002.
11. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. 2012. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56:2392-2396. http://dx.doi.org/10.1128/AAC.00028-12.
12. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP. 2015. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study. J Antimicrob Chemother 70:1552- 1557. http://dx.doi.org/10.1093/jac/dku561.
13. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65:431-434. http://dx.doi.org/10.1016/j.diagmicrobio.2009.07.018.
14. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: The second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
15. Cruz DN, Ricci Z, Ronco C. 2009. Clinical review: RIFLE and AKIN- Time for reappraisal. Crit Care 13:211. http://dx.doi.org/10.1186/cc7759.
16. Hoste EA, Clermont G, Kersten A, Venkataraman SR, Angus DC, De Bacquer D, Kellum JA. 2006. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit Care 10:R73. http://dx.doi.org/10.1186/cc4915.
17. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294http://dx.doi.org/10.1128/AAC.01733-10.
18. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
20. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: A severity of disease classification system. Crit Care Med 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
22. Pogue JM, Mudegowdra NS, Balakrishnan G, Salim M, Nishan B, Pervaiz A, Navalkele B, Shaikh H, Kaye KS. 2015. Lack of association between colistin loading dose and acute kidney injury (AKI), abstr A-981. Abstr 55th Intersci Conf Antimicrob Agents Chemother (ICAAC).
23. Zavascki AP. 2014. Polymyxins for the treatment of extensively-drugresistant Gram-negative bacteria: from pharmacokinetics to bedside. Expert Rev Anti Infect Ther 12:531-533. http://dx.doi.org/10.1586/14787210.2014.902307.
24. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect Dis 15:225-234. http://dx.doi.org/10.1016/S1473-3099(14)70850-3.
25. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gramnegative bacteria. Antimicrob Agents Chemother 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
26. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. http://dx.doi.org/10.1128/AAC.00280-12.